<DOC>
	<DOCNO>NCT00910039</DOCNO>
	<brief_summary>RATIONALE : Sunitinib malate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well sunitinib malate work stereotactic radiosurgery treat patient newly diagnose brain metastasis .</brief_summary>
	<brief_title>Sunitinib Malate After Stereotactic Radiosurgery Treating Patients With Newly Diagnosed Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine CNS progression-free survival rate patient 1-3 newly diagnose brain metastasis treat sunitinib malate stereotactic radiosurgery ( SRS ) . Secondary - Determine rate local ( site SRS treatment ) failure 12 month patient . - Determine median time CNS disease progression patient . - Determine overall survival patient . - Determine time progression systemic disease patient . - Evaluate safety sunitinib malate administer SRS patient . - Assess neurocognitive effect SRS follow sunitinib malate patient . OUTLINE : Patients receive oral sunitinib malate daily day 1-28 . Courses repeat every 42 day absence disease progression unacceptable toxicity . Patients undergo neuropsychological battery test baseline periodically study assess cognitive function ( memory , verbal fluency , visual-motor speed , executive function , motor dexterity ) , activity daily live , quality life .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm carcinoma Has 13 newly diagnose brain metastasis amenable stereotactic radiosurgery Patients may enroll 1 month completion stereotactic radiosurgery provide undergo require neuropsychiatric battery begin treatment . Patients must begin treatment within 1 month stereotactic radiosurgery . No CNS metastases lymphoma small cell lung cancer No leptomeningeal metastases No CNS complication require urgent neurosurgical intervention ( e.g. , resection shunt placement ) PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % ( RTOG RPA class I II ) Life expectancy &gt; 6 week ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL ( transfusion allow ) AST ALT ≤ 2.5 time upper limit normal ( ULN ) Total serum bilirubin ≤ 1.5 time ULN Serum calcium ≤ 12.0 mg/dL Serum creatinine ≤ 2.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Willing able comply schedule visit , treatment plan , laboratory test , study procedures No medical problem ( unrelated malignancy ) would pose undue risk would limit full compliance study No unresolved bowel obstruction No uncontrolled infectious process No evidence bleed diathesis coagulopathy Hematuria primary renal tumor allow provide eligibility criterion meet No hypertension control medication blood pressure &lt; 160/90 mm Hg None follow within past 6 month : Myocardial infarction Severe/unstable angina Severe peripheral vascular disease ( claudication ) procedure peripheral vasculature Coronary/peripheral artery bypass graft NYHA class IIIV congestive heart failure Cerebrovascular accident transient ischemic attack Clinically significant bleed Deep venous thrombosis pulmonary embolism No severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgement investigator , would make patient inappropriate entry study PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior sunitinib malate No prior cranial external beam radiotherapy No concurrent coumadin agent contain warfarin , except lowdose coumadin ( ≤ 1 mg ) administer prophylactically maintenance indwell line port No concurrent hepatic enzymeinducing anticonvulsant No concurrent participation another clinical trial No concurrent investigational agent Concurrent steroid allow provide dose stable ≥ 1 week Concurrent systemic therapy management stable systemic disease allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>cognitive/functional effect</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>